ERBB2 and breast carcinoma: Other proposed mechanisms of Herceptin's action include inhibition of basal and activated HER2 ectodomain cleavage in breast cancer cells [11], the induction of G1 arrest and cyclin-dependent kinase inhibitor p27Kip1 levels [12], or activation of PTEN [13].